Form 4: BioAtla CMO's Tax Withholding on RSU Vesting

BioAtla's Chief Medical Officer, Eric Sievers, had 2,729 shares withheld by the company to cover tax obligations related to the vesting of restricted stock units.

Summary

• Eric Sievers, Chief Medical Officer of BioAtla, Inc. (BCAB), reported a transaction on November 30, 2025.
• The transaction involved the disposition of 2,729 shares of common stock at a price of $0.904 per share.
• This disposition was not a sale by Mr. Sievers but represents shares withheld by BioAtla to satisfy income tax and withholding obligations.
• The withholding was in connection with the vesting and net settlement of previously reported restricted stock units.
• Following this transaction, Mr. Sievers beneficially owns 361,845 shares of BioAtla common stock directly.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary transaction related to executive compensation and tax obligations, which has a neutral impact on the company's operational or financial outlook.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

The withholding of shares for tax purposes upon the vesting of restricted stock units is a routine and common practice for executives in publicly traded companies across all industries, including biotechnology.

Comparison to Industry Standards

• This type of transaction (shares withheld for tax on RSU vesting) is a standard compensation practice and is consistent with how equity compensation is typically handled for executives in the biotechnology sector and broader public markets.
• It does not indicate any unusual activity compared to peers or industry benchmarks.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary tax event related to executive compensation, not a sale by the insider.
• Employees: No direct impact beyond the reporting person.

Key Dates

Recommendation

This Form 4 filing details a routine tax withholding event for an executive's restricted stock units. It does not reflect any discretionary trading activity, changes in company fundamentals, or new strategic information that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this event is neutral to the company's investment thesis.

Keywords

BioAtla, BCAB, Form 4, insider transaction, RSU, restricted stock units, tax withholding, Eric Sievers, Chief Medical Officer